Sugi Predict

Sugi Predict / Compounds / SCHEMBL833144

SCHEMBL833144

SCHEMBL833144

CCS(=O)(=O)NC(=O)c1c(-c2ccc[nH]c2=O)c2cc(C)ccc2n1Cc1ccccc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C8 P10632 1/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ MEN1 O00255 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ ECE1 P42892 1/20 0.36
▸ PTGDR2 Q9Y5Y4 4/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ PARG Q86W56 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ RORC P51449 1/20 0.35
▸ MGAM O43451 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ SI P14410 1/20 0.35
▸ MGAM2 Q2M2H8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL831577 0.92 CYP2C8 (0.46) CYP2C8KMT2AMEN1MAPTECE1
SCHEMBL832052 0.92 CYP2C8 (0.42) CYP2C8KMT2AMEN1PTGDR2RXFP1
SCHEMBL832360 0.91 CYP2C8 (0.43) CYP2C8KMT2AMEN1ECE1PTGDR2
SCHEMBL831530 0.91 CYP2C8 (0.43) CYP2C8KMT2AMEN1MAPTECE1
SCHEMBL831655 0.91 CYP2C8 (0.46) CYP2C8KMT2AMEN1MAPTPTGDR2
SCHEMBL831703 0.90 CYP2C8 (0.44) CYP2C8KMT2AMEN1MAPTECE1
SCHEMBL831702 0.90 CYP2C8 (0.42) CYP2C8KMT2AMEN1PTGDR2KDM4E
SCHEMBL830972 0.90 CYP2C8 (0.42) CYP2C8KMT2AMEN1ECE1PARG
SCHEMBL831674 0.89 CYP2C8 (0.43) CYP2C8KMT2AMEN1MAPTECE1
SCHEMBL831179 0.88 CYP2C8 (0.46) CYP2C8KMT2AMEN1MAPTECE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2197842-B1 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS SCHERING CORP (US) 2012-05-23 — — EP disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 — — US disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 — — US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 — — US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 — — US disclosed
WO-2009032116-A1 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS SCHERING CORPORATION (US) 2009-03-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 CYP2C8 847/4885KMT2A 321/4885MEN1 2084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.